Ahmad Al Tibi

Mr. Ahmad Al Tibi

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2025 in Viruses
Verified
Journal Article
Open access
PDF file
MAMunir Abu-Helalah
Munir Abu-Helalah
MLMohammad Abu Lubad
Mohammad Abu Lubad
MAMohammad Al-Hanaktah
Mohammad Al-Hanaktah
ATAhmad Al Tibi
Ahmad Al Tibi
MAMaisalreem Alhousani
Maisalreem Alhousani
SDSimon Drysdale
Simon Drysdale
Human parainfluenza virus (HPIV) is a major cause of respiratory illnesses in children under five years, with clinical manifestations ranging from mild upper respiratory tract infections to severe lower respiratory tract diseases. This multi-center, cross-sectional study investigated the burden, clinical features, and predictors of respiratory viral infections in hospitalized children across four sites in Jordan. Nasopharyngeal specimens from 1000 eligible children were analyzed. In this article, we focused on HPIV infections. The overall HPIV positivity rate was 22.6%, with HPIV-3 accounting for 90.3% of cases. Significant geographic variability was observed, with higher positivity rates in the southern region. HPIV-positive cases frequently presented with symptoms like nasal congestion, tachypnea, and poor feeding. Co-infections with respiratory syncytial virus (RSV) or influenza were associated with worse outcomes, including an increased need for invasive ventilation. The logistic regression identified male gender, asthma, and respiratory acidosis as predictors of complications. Geographic differences in HPIV prevalence and severity were notable, emphasizing the influence of environmental and socioeconomic factors. These findings underscore the urgent need for enhanced HPIV surveillance, targeted public health interventions, and vaccine development to mitigate the disease burden. This study provides critical insights that guide healthcare strategies and improve outcomes in young children at risk of severe HPIV infections.

14 June 2026 in Scientific Reports
Verified
Journal Article
Open access
IAIssa Abu-Dayyeh
Issa Abu-Dayyeh
HCHiam Chemaitelly
Hiam Chemaitelly
ATAhmad Al Tibi
Ahmad Al Tibi
MGMohammad Ghunaim
Mohammad Ghunaim
THThaer Hasan
Thaer Hasan
Laith Abu-RaddadLaith Abu-Raddad
Laith Abu-Raddad
Syphilis is a health priority targeted for elimination by 2030, yet its global epidemiology remains insufficiently characterized. The study analyzed data from 25,630 adults aged ≥ 15 years who underwent syphilis testing in Jordan at Biolab Diagnostic Laboratories during 2010-2025. Cross-sectional and retrospective cohort analyses were used to estimate prevalence, temporal trends, patterns of rapid plasma reagin (RPR) and Treponema pallidum pallidum hemagglutination assay (TPHA) reactivity, associated risk factors, and incidence rate. Syphilis prevalence (ever RPR- or TPHA-reactive) was 0.9% (95% CI: 0.8-1.0%) overall and only 0.08% (95% CI: 0.05-0.10%) among those tested for visa-related medical screening. RPR reactivity was 0.5% (95% CI: 0.4-0.6%), and among RPR-reactive individuals, 79.2% (95% CI: 65.0-89.5%) were TPHA-reactive within 30 days. Outpatient or walk-in visits, doctor referrals, and laboratory referrals showed substantially higher reactivity than visa-related medical screening, whereas sex, governorate, insurance status, and testing year showed no significant associations. Cumulative syphilis incidence was 0.18% (95% CI: 0.04-0.72%) after two years of follow-up, with an incidence rate of 0.92 per 1,000 person-years (95% CI: 0.23-3.68). Syphilis prevalence and incidence in Jordan are relatively low, but with no evidence of decline over 15 years, indicating limited progress toward elimination targets.

9 September 2025 in Journal of Viral Hepatitis
Verified
Journal Article
Open access
IAIssa Abu‐Dayyeh
Issa Abu‐Dayyeh
HCHiam Chemaitelly
Hiam Chemaitelly
ATAhmad Al Tibi
Ahmad Al Tibi
MGMohammad Ghunaim
Mohammad Ghunaim
THThaer Hasan
Thaer Hasan
Laith Abu-RaddadLaith Abu-Raddad
Laith Abu-Raddad
Hepatitis B virus (HBV) infection is a global health challenge, with the World Health Organization (WHO) targeting its elimination by 2030. Jordan lacks sufficient data on HBV epidemiology, including prevalence, incidence and clearance. This study addresses these gaps through a retrospective analysis of HBV testing data from 40,268 individuals collected at Biolab Diagnostic Laboratories (2010–2024). Using cross‐sectional and cohort study designs, the study examined hepatitis B surface antigen (HBsAg) prevalence, temporal trends, incidence, clearance rates and associated risk factors. Statistical methods included regression analyses, Kaplan–Meier estimations and Poisson models. HBsAg prevalence was 3.8% (95% CI: 3.6%–4.0%), with a nationally weighted prevalence of 5.3% (95% CI: 4.4%–6.4%). Prevalence was around 1% in individuals under 20 years, increasing to 8.5% (95% CI: 7.7%–10.0%) in the 50–59 age group. Over the past 15 years, prevalence declined by 7% annually [adjusted odds ratio (aOR): 0.93; 95% CI: 0.92–0.94]. HBsAg positivity was significantly associated with age, male sex and governorate. Cumulative HBsAg incidence was 0.26% (95% CI: 0.11%–0.64%) after 5 years of follow‐up, with an incidence rate of 0.63 per 1000 person‐years (95% CI: 0.26–1.51). Cumulative HBsAg clearance was 7.45% (95% CI: 4.07%–13.43%) at the 6‐month follow‐up mark, with a clearance rate of 17.68 per 100 person‐years (95% CI: 9.51–32.86). Among HBsAg‐positive individuals with > 6 months of follow‐up, cumulative HBsAg clearance reached 46.12% (95% CI: 24.50%–74.34%) after 13 years of follow‐up, with a clearance rate of 5.27 per 100 person‐years (95% CI: 3.32–8.36). HBV epidemiology in Jordan shows declining prevalence and incidence, likely driven by expanding HBV vaccination coverage. To meet the WHO's 2030 elimination targets, Jordan must prioritise scaling up birth‐dose vaccination, improving case detection and ensuring timely treatment.

3 July 2026 in BMC Public Health
Verified
Journal Article
Open access
IAIssa Abu-Dayyeh
Issa Abu-Dayyeh
ATAhmad Al Tibi
Ahmad Al Tibi
MGMohammad Ghunaim
Mohammad Ghunaim
THThaer Hasan
Thaer Hasan
AAAmid Abdelnour
Amid Abdelnour
HCHiam Chemaitelly
Hiam Chemaitelly
Gonorrhea is a global public health priority due to substantial morbidity, sustained transmission, and increasing antimicrobial resistance; however, its epidemiology in Jordan and other settings with limited surveillance and research, such as in the Middle East and North Africa, remains inadequately characterized. Data from 8,779 individuals aged ≥ 15 years tested for current Neisseria gonorrhoeae (NG) infection at Biolab Diagnostic Laboratories in Jordan between 2014 and 2025 were analyzed. A cross-sectional design was used to estimate prevalence, assess temporal trends, and identify factors associated with infection among all 8,779 individuals. Retrospective cohort designs were used to assess incidence among 784 individuals and, exploratorily, clearance among 5 individuals with repeat testing. NG prevalence, defined as ever having a NAAT-positive test, was 0.4% (95% CI: 0.2-0.5%) overall and 0.1% (95% CI: 0.0-0.2%) among individuals tested for visa-related requirements. Corresponding point prevalence, based on one randomly selected test per individual, was 0.3% (95% CI: 0.2-0.5%) and 0.1% (95% CI: 0.0-0.2%), respectively. NG positivity was substantially higher in clinically motivated testing compared with visa-related testing and among individuals with more frequent testing. No consistent patterns were observed by age, sex, or governorate, and there was no evidence of a temporal decline. In the retrospective cohort, three incident infections were identified over 1,167 person-years of follow-up, yielding a cumulative incidence of 0.49% (95% CI: 0.16-1.53%) after two years of follow-up and an incidence rate of 2.57 per 1,000 person-years (95% CI: 0.83-7.97). In exploratory analysis, nearly all individuals with follow-up after a positive test had a subsequent negative result within 10 days. Observed NG prevalence and incidence rate in Jordan were low. However, high positivity in clinically motivated testing contexts and the absence of a temporal decline indicate ongoing transmission that requires control. Strengthening surveillance, expanding targeted testing and treatment among higher-risk populations, and integrating NG antimicrobial resistance monitoring are needed to inform prevention and control efforts.

12 May 2026 in Pathogens
Verified
Journal Article
Open access
PDF file
MLMohammad Abu Lubad
Mohammad Abu Lubad
MAMunir Abu-Helalah
Munir Abu-Helalah
MAMohammad Al-Hanaktah
Mohammad Al-Hanaktah
MAMaisalreem Alhousani
Maisalreem Alhousani
JKJana Khatatbeh
Jana Khatatbeh
SDSimon Drysdale
Simon Drysdale
Human bocavirus (HBoV) is an important respiratory pathogen in young children, but recent data from Jordan are limited. This study assessed the positivity rate, epidemiological profile, clinical manifestations, and predictors of HBoV infection among hospitalized children aged <5 years in Jordan. In this national multicenter cross-sectional study, 1000 children aged <5 years admitted with acute respiratory infection to four hospitals in Jordan between November 2022 and March 2023 were included. Nasopharyngeal specimens were tested for HBoV, and demographic, clinical, and hospitalization data were analyzed using descriptive statistics and logistic regression. HBoV was detected in 48/1000 children (4.8%), with the highest positivity in January 2023 (15.5%). Fever (100%), cough (100%), rhinorrhea (56.3%), respiratory crackles (58.3%), and breathlessness (47.9%) were the most frequent manifestations. Pneumothorax/atelectasis was more frequent in HBoV-positive than HBoV-negative children (2.1% vs. 0.2%; p = 0.021). Household smoking, residence outside Amman, and longer hospital stay were independent predictors of HBoV positivity. HBoV infection was not independently associated with complications. HBoV accounted for a measurable proportion of pediatric respiratory hospitalizations in Jordan and remains a relevant contributor to respiratory morbidity in children under 5 years.